<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817800</url>
  </required_header>
  <id_info>
    <org_study_id>980-2020</org_study_id>
    <nct_id>NCT04817800</nct_id>
  </id_info>
  <brief_title>To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, &amp; Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray</brief_title>
  <official_title>An Open Label, Randomized, Three-treatment, Three-period, Crossover, Single Dose Study, to Investigate Drug-drug Interaction and Relative Bioavailability Between the Fixed Dose Combination Azelastine Hydrochloride / Beclomethasone Dipropionate (140/100 μg Azelastine Hydrochloride / Beclomethasone Dipropionate) Nasal Spray, and Beclomethasone Dipropionate Nasal Spray (100 μg Beclomethasone Dipropionate) in the Test Vehicle, and the Commercially Available Product, RinoClenil® Nasal Spray (100 μg Beclomethasone Dipropionate), in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmactive Ilac Sanayi ve Tic A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmactive Ilac Sanayi ve Tic A.S.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, randomized, three-treatment, three-period, crossover, single dose study, to&#xD;
      investigate drug-drug interaction and relative bioavailability between the fixed dose&#xD;
      combination Azelastine hydrochloride / Beclomethasone dipropionate (140/100 μg Azelastine&#xD;
      hydrochloride / Beclomethasone dipropionate) Nasal Spray, and Beclomethasone Dipropionate&#xD;
      Nasal Spray (100 μg Beclomethasone Dipropionate) in the test vehicle, and the commercially&#xD;
      available product, RinoClenil® Nasal Spray (100 μg Beclomethasone Dipropionate), in healthy&#xD;
      subjects under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Actual">April 10, 2021</completion_date>
  <primary_completion_date type="Actual">April 10, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of Beclomethasone dipropionate and its active metabolite Beclomethasone 17-monopropionate</measure>
    <time_frame>23 hours</time_frame>
    <description>For the assessment of a potential drug-drug interaction, no effect of Azelastine on the pharmacokinetics of Beclomethasone dipropionate and its active metabolite Beclomethasone 17-monopropionate will be concluded if the fixed dose combination Test-to-mono test GMR and the corresponding 90% CI of the ln-transformed primary pharmacokinetic parameters are within the 80.00% to 125.00% acceptance interval.&#xD;
For the assessment of the relative bioavailability, bioequivalence between Beclomethasone dipropionate drug products will be concluded if the fixed dose combination test-to-mono reference GMR and the corresponding 90% CI of the Lntransformed primary pharmacokinetic parameters are within the 80.00% to 125.00% acceptance interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the plasma concentration versus time curve (AUC) from pre-dose (time zero) to the last sampling time with quantifiable concentrations (AUC0-t) of Beclomethasone dipropionate and its active metabolite Beclomethasone 17-monopropionate</measure>
    <time_frame>23 hours</time_frame>
    <description>For the assessment of a potential drug-drug interaction, no effect of Azelastine on the pharmacokinetics of Beclomethasone dipropionate and its active metabolite Beclomethasone 17-monopropionate will be concluded if the fixed dose combination Test-to-mono test GMR and the corresponding 90% CI of the ln-transformed primary pharmacokinetic parameters are within the 80.00% to 125.00% acceptance interval.&#xD;
For the assessment of the relative bioavailability, bioequivalence between Beclomethasone dipropionate drug products will be concluded if the fixed dose combination test-to-mono reference GMR and the corresponding 90% CI of the Lntransformed primary pharmacokinetic parameters are within the 80.00% to 125.00% acceptance interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero to infinity (AUC0-∞) of Beclomethasone dipropionate and its active metabolite Beclomethasone 17-monopropionate</measure>
    <time_frame>23 hours</time_frame>
    <description>For the assessment of a potential drug-drug interaction, no effect of Azelastine on the pharmacokinetics of Beclomethasone dipropionate and its active metabolite Beclomethasone 17-monopropionate will be concluded if the fixed dose combination Test-to-mono test GMR and the corresponding 90% CI of the ln-transformed primary pharmacokinetic parameters are within the 80.00% to 125.00% acceptance interval.&#xD;
For the assessment of the relative bioavailability, bioequivalence between Beclomethasone dipropionate drug products will be concluded if the fixed dose combination test-to-mono reference GMR and the corresponding 90% CI of the Lntransformed primary pharmacokinetic parameters are within the 80.00% to 125.00% acceptance interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obtaining the Tmax (Time to reach maximum concentration)</measure>
    <time_frame>23 hours</time_frame>
    <description>The descriptive statistics including Maximum, Minimum and Median values will be measured for Tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (safety and tolerability)</measure>
    <time_frame>At 1 hour pre-dosing and 2, 4, 6, 8, 12, and 23 hours post dosing,</time_frame>
    <description>Clinically significant abnormal deviations. Normal range of blood pressure &gt; 90/60 and &lt;140/90 mmHg. Treatment will be offered to those subjects whom blood pressure drops to 90/60 mm Hg or less and the subject will be excluded in case of not responding to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse (safety and tolerability)</measure>
    <time_frame>At 1 hour pre-dosing and 2, 4, 6, 8, 12, and 23 hours post dosing,</time_frame>
    <description>Clinically significant abnormal deviations. Normal range of Pulse 60-100 Bpm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature (safety and tolerability)</measure>
    <time_frame>At 1 hour pre-dosing and 2, 6, 10, 14, 18, 22 and 23 hours post dosing,</time_frame>
    <description>Clinically significant abnormal deviations. The temperature will be measured axillary, orally or using infrared thermometer, standardized across all subjects. Normal range of temperature 36.5-37.5 ºC.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 μg Beclomethasone dipropionate, Nasal Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RinoClenil® Nasal Spray (100 μg Beclomethasone Dipropionate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)</intervention_name>
    <description>It will be nasaly administered</description>
    <arm_group_label>100 μg Beclomethasone dipropionate, Nasal Spray</arm_group_label>
    <arm_group_label>140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)</arm_group_label>
    <arm_group_label>RinoClenil® Nasal Spray (100 μg Beclomethasone Dipropionate)</arm_group_label>
    <other_name>100 μg Beclomethasone dipropionate, Nasal Spray</other_name>
    <other_name>RinoClenil® Nasal Spray (100 μg Beclomethasone Dipropionate)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is Caucasian &amp; aged between eighteen &amp; fifty years (18 - 50), both&#xD;
             inclusive.&#xD;
&#xD;
          -  The subject is within the limits for his height &amp; weight as defined by the body mass&#xD;
             index range&#xD;
&#xD;
          -  (18.5 - 30.0 Kg/m2).&#xD;
&#xD;
          -  The subject is willing to undergo the necessary pre- &amp; post- medical examinations set&#xD;
             by this&#xD;
&#xD;
          -  study.&#xD;
&#xD;
          -  The results of medical history, vital signs, physical examination &amp; conducted medical&#xD;
             laboratory&#xD;
&#xD;
          -  tests are normal as determined by the clinical investigator.&#xD;
&#xD;
          -  The subject tested negative for hepatitis (HBsAg, HCVAb) viruses and human&#xD;
             immunodeficiency&#xD;
&#xD;
          -  virus (HIVAb).&#xD;
&#xD;
          -  There is no evidence of psychiatric disorder, antagonistic personality and poor&#xD;
             motivation,&#xD;
&#xD;
          -  emotional or intellectual problems likely to limit the validity of consent to&#xD;
             participate in the study&#xD;
&#xD;
          -  or limit the ability to comply with protocol requirements.&#xD;
&#xD;
          -  The subject is able to understand and willing to sign the informed consent form.&#xD;
&#xD;
          -  For female subjects: negative pregnancy test and the woman is using two reliable&#xD;
             contraception&#xD;
&#xD;
          -  methods &amp; should be non-lactating.&#xD;
&#xD;
          -  The subject has normal cardiovascular system and ECG recording.&#xD;
&#xD;
          -  The subject kidney and liver (AST &amp; ALT enzymes) functions tests are within normal&#xD;
             range.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is smoker/ has positive cotinine test.&#xD;
&#xD;
          -  The subject has suffered an acute illness one week before dosing.&#xD;
&#xD;
          -  The subject has a history of or concurrent abuse of alcohol.&#xD;
&#xD;
          -  The subject has a history of or concurrent abuse of illicit drugs.&#xD;
&#xD;
          -  The subject has a history of hypersensitivity and/or contraindications to the study&#xD;
             drug, its&#xD;
&#xD;
          -  excipients and any related compounds.&#xD;
&#xD;
          -  The subject has been hospitalized within three months before the study or during the&#xD;
             study.&#xD;
&#xD;
          -  The subject is vegetarian.&#xD;
&#xD;
          -  The subject has consumed caffeine or xanthine containing beverages or foodstuffs&#xD;
             within two days&#xD;
&#xD;
          -  before dosing and until 23 hours after dosing in all study periods.&#xD;
&#xD;
          -  The subject has taken a prescription medication within two weeks or even an over the&#xD;
             counter&#xD;
&#xD;
          -  product (OTC) within one week before dosing in each study period and any time during&#xD;
             the study,&#xD;
&#xD;
          -  unless otherwise judged acceptable by the clinical investigator.&#xD;
&#xD;
          -  The subject has taken grapefruit containing beverages or foodstuffs within seven (7)&#xD;
             days before&#xD;
&#xD;
          -  first dosing and any time during the study.&#xD;
&#xD;
          -  The subject has been participating in any clinical study (e.g. pharmacokinetics,&#xD;
             bioavailability and&#xD;
&#xD;
          -  bioequivalence studies) within the last 80 days prior to the present study.&#xD;
&#xD;
          -  The subject has donated blood within 80 days before first dosing.&#xD;
&#xD;
          -  The subject has a history or presence of cardiovascular, pulmonary, renal, hepatic,&#xD;
             gastrointestinal,&#xD;
&#xD;
          -  hematological, endocrinal, immunological, dermatological, neurological,&#xD;
             musculoskeletal or&#xD;
&#xD;
          -  psychiatric diseases.&#xD;
&#xD;
          -  The subject has consumed drugs that may affect pharmacological or pharmacokinetic&#xD;
             properties&#xD;
&#xD;
          -  (ritonavir, cobicistat &amp; CNS depressants) two weeks before dosing, during the study&#xD;
             and two&#xD;
&#xD;
          -  weeks after dosing.&#xD;
&#xD;
          -  The subject has recent nose surgery or a history of chronic sinusitis, recent URTI and&#xD;
             nasal septum&#xD;
&#xD;
          -  deviation that may affect nasal mucosa integrity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ACDIMA Biocenter</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelastine</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

